GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Shares Outstanding (EOP)

TRAW (Traws Pharma) Shares Outstanding (EOP) : 3.03 Mil (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Traws Pharma's shares outstanding for the quarter that ended in Sep. 2024 was 3.03 Mil.

Traws Pharma's quarterly shares outstanding increased from Jun. 2024 (1.01 Mil) to Sep. 2024 (3.03 Mil). It means Traws Pharma issued new shares from Jun. 2024 to Sep. 2024 .

Traws Pharma's annual shares outstanding increased from Dec. 2022 (0.84 Mil) to Dec. 2023 (0.84 Mil). It means Traws Pharma issued new shares from Dec. 2022 to Dec. 2023 .


Traws Pharma Shares Outstanding (EOP) Historical Data

The historical data trend for Traws Pharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Shares Outstanding (EOP) Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.50 0.84 0.84 0.84

Traws Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.84 0.84 1.01 3.03

Competitive Comparison of Traws Pharma's Shares Outstanding (EOP)

For the Biotechnology subindustry, Traws Pharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Shares Outstanding (EOP) falls into.



Traws Pharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Traws Pharma  (NAS:TRAW) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Traws Pharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma Business Description

Traded in Other Exchanges
N/A
Address
12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022